RARE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $5,325,628.52

Ultragenyx Pharmaceutical Insider Trading History Chart

Ultragenyx Pharmaceutical Share Price & Price History

^$43.31

▼ -0.97 (-2.19%)

As of 04/25/2024 11:51 AM ET

Days: 30 | 90 | 365

This Apple-like Innovator is Revolutionizing Healthcare

From Wall Street Star | Ad

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Ultragenyx Pharmaceutical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2024	Eric Crombez	EVP	Sell	142	$44.10	$6,262.20	48,785
3/11/2024	Thomas Richard Kassberg	EVP	Sell	11,509	$49.93	$574,644.37	252,823
3/7/2024	Matthew K Fust	Director	Sell	12,195	$50.88	$620,481.60	14,860
3/1/2024	John Richard Pinion	Insider	Sell	4,173	$53.76	$224,340.48	89,268
3/1/2024	Karah Herdman Parschauer	EVP	Sell	3,756	$53.76	$201,922.56	67,340
3/1/2024	Theodore Alan Huizenga	CAO	Sell	341	$53.76	$18,332.16	41,380
10/23/2023	Thomas Richard Kassberg	EVP	Sell	39,878	$32.78	$1,307,200.84	246,860
10/19/2023	Emil D Kakkis	CEO	Sell	47,853	$33.52	$1,604,032.56	599,743
9/7/2023	Theodore Alan Huizenga	CAO	Sell	2,163	$40.80	$88,250.40	23,614
9/5/2023	Erik Harris	EVP	Sell	6,000	$37.96	$227,760.00	51,281
9/1/2023	Theodore Alan Huizenga	CAO	Sell	970	$37.15	$36,035.50	23,777
6/30/2023	Corsee D. Sanders	Director	Sell	585	$46.76	$27,354.60	8,985
6/19/2023	Erik Harris	EVP	Sell	305	$48.20	$14,701.00	57,281
6/8/2023	Corsee D. Sanders	Director	Sell	1,485	$51.65	$76,700.25	9,570
5/18/2023	John Richard Pinion	Insider	Sell	2,012	$50.00	$100,600.00	74,744
5/4/2023	Karah Herdman Parschauer	EVP	Sell	4,378	$45.00	$197,010.00	51,982
3/1/2023	Camille L. Bedrosian	EVP	Sell	3,881	$45.25	$175,615.25	46,720
3/1/2023	Dennis Karl Huang	Insider	Sell	389	$45.65	$17,757.85	75,314
2/28/2023	Theodore Alan Huizenga	CAO	Sell	639	$43.40	$27,732.60	15,558
12/21/2022	Theodore Alan Huizenga	CAO	Sell	2,031	$43.96	$89,282.76	16,197
10/14/2022	Mardi Dier	CFO	Sell	1,629	$40.16	$65,420.64	66,695
10/12/2022	Mardi Dier	CFO	Sell	3,484	$38.22	$133,158.48	68,324
6/19/2022	Erik Harris	EVP	Sell	295	$54.78	$16,160.10	36,160
4/16/2022	Theodore Alan Huizenga	CAO	Sell	132	$84.55	$11,160.60	16,914
3/11/2022	Thomas Richard Kassberg	EVP	Sell	10,281	$67.01	$688,929.81
3/7/2022	Karah Herdman Parschauer	EVP	Sell	5,140	$62.95	$323,563.00
3/1/2022	Erik Harris	EVP	Sell	2,713	$66.62	$180,740.06
3/1/2022	John Richard Pinion	Insider	Sell	4,498	$66.62	$299,656.76
1/30/2022	Camille L. Bedrosian	EVP	Sell	1,657	$66.30	$109,859.10
10/14/2021	Camille L. Bedrosian	EVP	Sell	359	$81.14	$29,129.26
10/14/2021	John Richard Pinion	Insider	Sell	358	$81.14	$29,048.12
10/14/2021	Mardi Dier	CFO	Sell	3,261	$81.16	$264,662.76
10/14/2021	Theodore Alan Huizenga	CAO	Sell	140	$81.14	$11,359.60
10/12/2021	Mardi Dier	CFO	Sell	3,477	$82.79	$287,860.83
9/8/2021	Karah Herdman Parschauer	EVP	Sell	7,336	$100.65	$738,368.40	36,004
9/1/2021	Camille L. Bedrosian	EVP	Sell	2,500	$100.03	$250,075.00
7/6/2021	Erik Harris	EVP	Sell	375	$91.53	$34,323.75
6/21/2021	Erik Harris	EVP	Sell	572	$94.96	$54,317.12	26,280
6/19/2021	Erik Harris	EVP	Sell	437	$94.63	$41,353.31	26,280
6/10/2021	Karah Herdman Parschauer	EVP	Sell	1,329	$100.00	$132,900.00
5/6/2021	Dennis Karl Huang	EVP	Sell	363	$113.68	$41,265.84
5/6/2021	Theodore Alan Huizenga	CAO	Sell	142	$113.67	$16,141.14
5/3/2021	Emil D. Kakkis	CEO	Sell	30,000	$107.80	$3,234,000.00

Wall Street Legend Issues New NVDA Warning

From Chaikin Analytics | Ad

Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.

Click here for the stock details

SEC Filings (Institutional Ownership Changes) for Ultragenyx Pharmaceutical (NASDAQ:RARE)

97.67% of Ultragenyx Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ultragenyx Pharmaceutical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/24/2024	Assenagon Asset Management S.A.	142,174	$6.64M	0.0%	-0.3%	0.173%
4/18/2024	Allspring Global Investments Holdings LLC	3,318	$0.16M	0.0%	+67.7%	0.004%
4/17/2024	Hennion & Walsh Asset Management Inc.	49,537	$2.31M	0.1%	+40.0%	0.060%
4/9/2024	Woodstock Corp	11,124	$0.52M	0.1%	+38.0%	0.014%
4/5/2024	GAMMA Investing LLC	1,004	$47K	0.0%	+622.3%	0.001%
3/11/2024	Vanguard Group Inc.	8,673,432	$414.76M	0.0%	+19.9%	10.534%
3/5/2024	Wellington Management Group LLP	4,415,029	$211.13M	0.0%	-15.0%	5.362%
2/20/2024	Quarry LP	2,200	$0.11M	0.0%	-47.6%	0.003%
2/15/2024	Great Point Partners LLC	648,000	$30.99M	5.3%	-10.9%	0.789%
2/14/2024	First Light Asset Management LLC	744,665	$35.61M	2.9%	-33.8%	0.907%
2/14/2024	Avidity Partners Management LP	844,500	$40.38M	1.5%	+55.2%	1.028%
2/14/2024	Avoro Capital Advisors LLC	350,000	$16.74M	0.2%	-76.7%	0.426%
2/14/2024	Ghisallo Capital Management LLC	10,000	$0.48M	0.0%	N/A	0.012%
2/14/2024	Seven Eight Capital LP	45,906	$2.20M	0.3%	+140.7%	0.056%
2/14/2024	RTW Investments LP	6,887,086	$329.34M	5.2%	+27.4%	8.388%
2/14/2024	Angeles Investment Advisors LLC	4,447	$0.21M	0.0%	N/A	0.005%
2/13/2024	Tower Research Capital LLC TRC	1,378	$66K	0.0%	-61.4%	0.002%
2/13/2024	First Trust Advisors LP	1,163,077	$55.62M	0.1%	-3.2%	1.416%
2/13/2024	Rafferty Asset Management LLC	221,910	$10.61M	0.0%	+21.2%	0.270%
2/13/2024	NEOS Investment Management LLC	10,797	$0.52M	0.0%	N/A	0.013%
2/13/2024	The Manufacturers Life Insurance Company	272,339	$13.02M	0.0%	+13.1%	0.332%
2/13/2024	Sands Capital Management LLC	4,118,008	$196.92M	0.6%	+59.8%	5.015%
2/12/2024	Treasurer of the State of North Carolina	34,853	$1.67M	0.0%	+17.3%	0.042%
2/12/2024	TD Asset Management Inc	221,360	$10.59M	0.0%	+7.8%	0.270%
2/12/2024	Pier 88 Investment Partners LLC	20,590	$0.99M	0.2%	+76.3%	0.025%
2/9/2024	Franklin Resources Inc.	214,738	$10.27M	0.0%	+13.3%	0.262%
2/9/2024	GW&K Investment Management LLC	307,529	$14.71M	0.1%	-1.1%	0.375%
2/9/2024	Trexquant Investment LP	53,500	$2.56M	0.1%	+81.1%	0.065%
2/9/2024	Clearbridge Investments LLC	2,383,492	$113.98M	0.1%	+3.9%	2.903%
2/9/2024	Norges Bank	770,506	$36.85M	0.0%	N/A	0.938%
2/8/2024	Great Lakes Advisors LLC	27,773	$1.33M	0.0%	-49.9%	0.034%
2/8/2024	EFG Asset Management North America Corp.	68,468	$3.27M	0.6%	+18.2%	0.083%
2/8/2024	Mitsubishi UFJ Asset Management Co. Ltd.	6,325	$0.30M	0.0%	+13.6%	0.008%
2/7/2024	Principal Financial Group Inc.	16,707	$0.80M	0.0%	-5.2%	0.020%
2/7/2024	BNP Paribas Financial Markets	157,281	$7.52M	0.0%	-26.6%	0.192%
2/7/2024	Teacher Retirement System of Texas	16,578	$0.79M	0.0%	-17.4%	0.020%
2/7/2024	E Fund Management Co. Ltd.	11,871	$0.57M	0.0%	+26.2%	0.014%
2/6/2024	Charles Schwab Investment Management Inc.	471,825	$22.56M	0.0%	+18.9%	0.575%
2/6/2024	Maryland State Retirement & Pension System	6,111	$0.29M	0.0%	N/A	0.007%
2/6/2024	M&T Bank Corp	6,486	$0.31M	0.0%	N/A	0.008%
2/6/2024	Amalgamated Bank	15,716	$0.75M	0.0%	+10.0%	0.019%
2/6/2024	Natixis Advisors L.P.	15,289	$0.73M	0.0%	+10.8%	0.019%
2/6/2024	Swiss National Bank	141,552	$6.77M	0.0%	-9.1%	0.172%
2/5/2024	Victory Capital Management Inc.	10,565	$0.51M	0.0%	+44.6%	0.013%
2/5/2024	Certuity LLC	9,145	$0.44M	0.0%	N/A	0.011%
2/5/2024	Van ECK Associates Corp	1,578	$75K	0.0%	+34.0%	0.002%
2/5/2024	Sector Gamma AS	102,490	$4.90M	1.2%	-11.0%	0.125%
2/5/2024	Russell Investments Group Ltd.	200,615	$9.59M	0.0%	+9.1%	0.244%
2/2/2024	Motley Fool Wealth Management LLC	164,235	$7.86M	0.4%	-2.4%	0.200%
2/2/2024	Truist Financial Corp	11,723	$0.56M	0.0%	-38.3%	0.014%
2/2/2024	Motley Fool Asset Management LLC	149,443	$7.15M	0.5%	-4.3%	0.182%
2/2/2024	State of New Jersey Common Pension Fund D	65,068	$3.11M	0.0%	-4.8%	0.079%
2/1/2024	New York State Common Retirement Fund	72,866	$3.48M	0.0%	+37.0%	0.089%
2/1/2024	Duality Advisers LP	39,371	$1.88M	0.2%	+45.6%	0.048%
2/1/2024	EFG Asset Management Americas Corp.	5,274	$0.25M	0.1%	N/A	0.006%
2/1/2024	Signaturefd LLC	677	$32K	0.0%	-26.2%	0.001%
1/31/2024	abrdn plc	141,117	$6.75M	0.0%	N/A	0.172%
1/31/2024	Xponance Inc.	10,162	$0.49M	0.0%	+6.8%	0.012%
1/31/2024	Federated Hermes Inc.	2,446,500	$116.99M	0.3%	+11.4%	2.980%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	16,147	$0.77M	0.0%	+14.2%	0.020%
1/30/2024	Cornercap Investment Counsel Inc.	5,146	$0.25M	0.0%	N/A	0.006%
1/29/2024	WCM Investment Management LLC	120,985	$5.84M	0.0%	+12.3%	0.147%
1/26/2024	Peregrine Capital Management LLC	119,300	$5.71M	0.2%	-14.7%	0.145%
1/25/2024	Allspring Global Investments Holdings LLC	1,979	$95K	0.0%	+38.3%	0.002%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	108,355	$5.18M	0.0%	-48.6%	0.132%
1/24/2024	DekaBank Deutsche Girozentrale	57,000	$2.75M	0.0%	+42.5%	0.069%
1/24/2024	International Assets Investment Management LLC	1,674	$80K	0.0%	+3,182.4%	0.002%
1/24/2024	China Universal Asset Management Co. Ltd.	9,501	$0.45M	0.1%	+418.9%	0.012%
1/23/2024	UMB Bank n.a.	606	$29K	0.0%	+118.8%	0.001%
1/17/2024	Assenagon Asset Management S.A.	142,541	$6.82M	0.0%	-32.4%	0.174%
1/16/2024	Raymond James Financial Services Advisors Inc.	19,578	$0.94M	0.0%	-11.4%	0.024%
1/16/2024	Raymond James & Associates	14,755	$0.71M	0.0%	-16.9%	0.018%
1/12/2024	SG Americas Securities LLC	9,199	$0.44M	0.0%	-24.3%	0.011%
1/10/2024	Nordea Investment Management AB	45,465	$2.17M	0.0%	-2.0%	0.055%
1/8/2024	Woodstock Corp	8,060	$0.39M	0.0%	N/A	0.010%
1/8/2024	Harbor Capital Advisors Inc.	34,930	$1.67M	0.3%	+9.6%	0.043%
12/19/2023	Public Employees Retirement System of Ohio	27,551	$0.98M	0.0%	-10.0%	0.034%
12/18/2023	Vanguard Group Inc.	7,233,168	$257.86M	0.0%	+3.1%	8.809%
12/7/2023	Hudson Bay Capital Management LP	734,272	$26.18M	0.2%	+46.3%	0.894%
12/1/2023	Wellington Management Group LLP	5,195,880	$185.23M	0.0%	+0.4%	6.328%
11/24/2023	Deutsche Bank AG	947,732	$33.79M	0.0%	+6.8%	1.154%
11/17/2023	Jacobs Levy Equity Management Inc.	748,278	$26.68M	0.2%	+23.8%	0.911%
11/15/2023	Crestwood Advisors Group LLC	100,258	$3.57M	0.1%	+235.2%	0.122%
11/15/2023	Rock Springs Capital Management LP	1,476,441	$52.64M	1.4%	+6.7%	1.798%
11/15/2023	Sands Capital Management LLC	2,577,217	$91.88M	0.3%	-3.6%	3.139%
11/15/2023	Seven Eight Capital LP	19,075	$0.68M	0.1%	+38.2%	0.023%
11/15/2023	Adage Capital Partners GP L.L.C.	90,000	$3.21M	0.0%	-16.4%	0.110%
11/14/2023	Corton Capital Inc.	8,856	$0.32M	0.2%	+46.1%	0.011%
11/14/2023	Fred Alger Management LLC	638,866	$22.78M	0.1%	-2.6%	0.778%
11/14/2023	Avidity Partners Management LP	544,000	$19.39M	0.8%	-39.6%	0.663%
11/14/2023	Bank of Nova Scotia	42,451	$1.51M	0.0%	N/A	0.052%
11/14/2023	Trexquant Investment LP	29,548	$1.05M	0.0%	+2.3%	0.036%
11/14/2023	Profund Advisors LLC	30,061	$1.07M	0.1%	+4.7%	0.037%
11/13/2023	Natixis Advisors L.P.	13,793	$0.49M	0.0%	-12.4%	0.017%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	182,235	$6.50M	0.0%	-11.5%	0.222%
11/13/2023	Covestor Ltd	748	$27K	0.0%	+392.1%	0.001%
11/13/2023	CHI Advisors LLC	215,000	$7.67M	2.3%	+152.9%	0.262%
11/13/2023	Algert Global LLC	22,140	$0.79M	0.0%	-17.5%	0.027%
11/13/2023	Federated Hermes Inc.	2,196,500	$78.31M	0.2%	+23.6%	2.675%
11/13/2023	Motley Fool Asset Management LLC	156,104	$5.57M	0.4%	+70.3%	0.190%

Data available starting January 2016

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $43.31

$42.83

$44.00

50 Day Range

MA: $47.94

$42.31

$53.69

52 Week Range

Now: $43.31

$31.52

$54.98

Volume

64,035 shs

Average Volume

753,487 shs

Market Capitalization

$3.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Who are the company insiders with the largest holdings of Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical's top insider shareholders include:
Emil D Kakkis (CEO)
Thomas Richard Kassberg (EVP)
John Richard Pinion (Insider)
Dennis Karl Huang (Insider)
Mardi Dier (CFO)
Karah Herdman Parschauer (EVP)
Erik Harris (EVP)
Eric Crombez (EVP)
Camille L Bedrosian (EVP)
Theodore Alan Huizenga (CAO)
Matthew K Fust (Director)
Corazon (Corsee) D Sanders (Director)
Learn More about top insider investors at Ultragenyx Pharmaceutical.
Who are the major institutional investors of Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical's top institutional investors include:
Assenagon Asset Management S.A. — 0.17%
Hennion & Walsh Asset Management Inc. — 0.06%
Woodstock Corp — 0.01%
Allspring Global Investments Holdings LLC — 0.00%
GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Ultragenyx Pharmaceutical stock.
Which major investors are selling Ultragenyx Pharmaceutical stock?: During the last quarter, RARE stock was sold by these institutional investors:
Assenagon Asset Management S.A.
During the previous year, company insiders that have sold Ultragenyx Pharmaceutical company stock include:
Emil D Kakkis (CEO)
Thomas Richard Kassberg (EVP)
John Richard Pinion (Insider)
Dennis Karl Huang (Insider)
Mardi Dier (CFO)
Karah Herdman Parschauer (EVP)
Erik Harris (EVP)
Eric Crombez (EVP)
Camille L Bedrosian (EVP)
Learn More investors selling Ultragenyx Pharmaceutical stock.
Which major investors are buying Ultragenyx Pharmaceutical stock?: During the last quarter, RARE stock was purchased by institutional investors including:
Hennion & Walsh Asset Management Inc.
Woodstock Corp
Allspring Global Investments Holdings LLC
GAMMA Investing LLC